Novo Nordisk A/S — Sponsor Intelligence | 107 EU Trials

Filter these 107 trials by condition, phase, country and more.

Open in Search →

107 Registered trials

29 Recruiting

72 Completed trials

25 Countries active

40 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 49 Phase II/III: 1 Phase II: 13 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I: 13 Phase I (Other): 24 Other: 3

Oversight events:

11 serious breaches 1 temporary halt 1 corrective measure across 9 trials

View oversight register →

100%

72 of 72 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Obesity 9 Sickle cell disease 3 Overweight 2 Cardiac failure 2 Non-alcoholic steatohepatitis 2 Acute myocardial infarction 1 Chronic kidney disease 1 Type 2 diabetes mellitus 1 Cardiovascular disorder 1 Turner's syndrome 1 Noonan syndrome 1 Alcoholic liver disease 1

Top IMPs

SEMAGLUTIDE 19 CAGRILINTIDE, SEMAGLUTIDE 12 ZENAGAMTIDE 9 CAGRILINTIDE 7 INSULIN GLARGINE 5 ZILTIVEKIMAB 5 ETAVOPIVAT 4 INSULIN ICODEC 4 SOMAPACITAN 4 CORAMITUG 3 SOMATROPIN 3 CONCIZUMAB 2

All trials — page 2

107 total

A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity Recruiting

2025-521393-34-00 Phase I (Other) 1 country
Effects of ziltivekimab on coronary atherosclerotic burden in patients with acute myocardial infarction Recruiting

2024-520364-34-00 Phase III 5 countries ZILTIVEKIMAB
A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people wit… Recruiting

2024-519372-22-00 Phase I (Other) 1 country
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes Recruiting

2024-519382-22-00 Phase I 1 country
A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting

2023-509175-16-00 Phase III 6 countries ETAVOPIVAT
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A Recruiting

2025-520490-38-00 Phase I (Other) 7 countries
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Recruiting

2024-519945-31-00 Phase III 4 countries INSULIN GLARGINE; INSULIN ICODEC
"A research study comparing different doses of CDR132L with placebo on the structure and function of the heart in people with heart failure … Recruiting

2024-515796-35-00 Phase II 3 countries
A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting

2024-515797-27-00 Phase II 5 countries
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Recruiting

2024-517883-49-00 Phase I (Other) 1 country
A research study looking at long-term treatment with etavopivat in people with sickle cell disease or thalassaemia Recruiting

2024-510805-27-00 Phase III 5 countries ETAVOPIVAT
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Phase III 5 countries CAGRILINTIDE
Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide Ended

2024-519531-41-00 Phase III 5 countries CAGRILINTIDE
A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabe… Ended

2024-519533-38-00 Phase I (Other) 1 country
A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn… Ended

2024-510846-15-00 Phase II 4 countries NNC0519-0130; SEMAGLUTIDE
STEP TEENS Weight Maintenance: A research study on how well semaglutide helps teenagers with excess body weight to lose weight and maintain … Ended

2023-508055-40-00 Phase IV 8 countries SEMAGLUTIDE
A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended

2023-509662-38-00 Phase II 4 countries CAGRILINTIDE, SEMAGLUTIDE
A research study to look into the long-term effect on weight loss of CagriSema in people with obesity Ended

2024-512144-39-00 Phase III 3 countries CAGRILINTIDE, SEMAGLUTIDE
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Phase III 6 countries CAGRILINTIDE, SEMAGLUTIDE; TIRZEPATIDE
A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin a… Ended

2022-502605-15-00 Phase II 7 countries CORAMITUG
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 Phase III 10 countries ZILTIVEKIMAB
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Phase III 7 countries ZILTIVEKIMAB
STEP Young: A research study on how well semaglutide helps children and teenagers with excess body weight lose weight Ended

2022-502922-41-00 Phase III 6 countries SEMAGLUTIDE
A research study looking at how safe somapacitan is and how well it works in children who need help to grow – REAL 9 Ended

2022-501055-87-01 Phase III 3 countries SOMAPACITAN

Showing 25–48 of 107 trials

← All sponsors A–Z